Phase II study of low-dose topotecan in myelodysplastic syndromes: A Hoosier Oncology Group (HOG) study

Daniel A. Vaena, Paul Walker, Kenneth Pennington, Anthony Stephens, Michael J. Stender, Constantin T. Yiannoutsos, Carol Young, Cindy Stoner, Larry D. Cripe

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Topotecan has demonstrable activity in high-risk MDS and CMMoL. However, the significant toxicity of topotecan administered at a dose of 2mg/m 2 i.v. daily for 5 days as a continuous infusion limits its use in older patients. Therefore, we studied topotecan 1.5mg/m2 per day i.v. over 2h for three consecutive days in 20 patients with high-risk MDS (12 RAEB; 4 RAEB-T; 4 CMMoL). Cycles were given every 4-6 weeks. Fifteen patients were evaluable for response. Only one patient achieved a durable complete remission (CR). There were three deaths within the first cycle of therapy. Severe myelosupression was the most common toxicity. Grades 3-4 infections were documented in four patients. We conclude that topotecan administered at this dose and schedule has no clinically significant activity.

Original languageEnglish (US)
Pages (from-to)49-52
Number of pages4
JournalLeukemia Research
Volume28
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Topotecan
Myelodysplastic Syndromes
Refractory Anemia with Excess of Blasts
Appointments and Schedules
Infection

Keywords

  • Acute myeloid leukemia
  • Induction
  • Low-dose chemotherapy
  • Mortality
  • Myelodysplastic syndromes
  • Topotecan

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Phase II study of low-dose topotecan in myelodysplastic syndromes : A Hoosier Oncology Group (HOG) study. / Vaena, Daniel A.; Walker, Paul; Pennington, Kenneth; Stephens, Anthony; Stender, Michael J.; Yiannoutsos, Constantin; Young, Carol; Stoner, Cindy; Cripe, Larry.

In: Leukemia Research, Vol. 28, No. 1, 01.2004, p. 49-52.

Research output: Contribution to journalArticle

Vaena, Daniel A. ; Walker, Paul ; Pennington, Kenneth ; Stephens, Anthony ; Stender, Michael J. ; Yiannoutsos, Constantin T. ; Young, Carol ; Stoner, Cindy ; Cripe, Larry D. / Phase II study of low-dose topotecan in myelodysplastic syndromes : A Hoosier Oncology Group (HOG) study. In: Leukemia Research. 2004 ; Vol. 28, No. 1. pp. 49-52.
@article{e7f1b93aa7c840aebefe99349c52ae65,
title = "Phase II study of low-dose topotecan in myelodysplastic syndromes: A Hoosier Oncology Group (HOG) study",
abstract = "Topotecan has demonstrable activity in high-risk MDS and CMMoL. However, the significant toxicity of topotecan administered at a dose of 2mg/m 2 i.v. daily for 5 days as a continuous infusion limits its use in older patients. Therefore, we studied topotecan 1.5mg/m2 per day i.v. over 2h for three consecutive days in 20 patients with high-risk MDS (12 RAEB; 4 RAEB-T; 4 CMMoL). Cycles were given every 4-6 weeks. Fifteen patients were evaluable for response. Only one patient achieved a durable complete remission (CR). There were three deaths within the first cycle of therapy. Severe myelosupression was the most common toxicity. Grades 3-4 infections were documented in four patients. We conclude that topotecan administered at this dose and schedule has no clinically significant activity.",
keywords = "Acute myeloid leukemia, Induction, Low-dose chemotherapy, Mortality, Myelodysplastic syndromes, Topotecan",
author = "Vaena, {Daniel A.} and Paul Walker and Kenneth Pennington and Anthony Stephens and Stender, {Michael J.} and Constantin Yiannoutsos and Carol Young and Cindy Stoner and Larry Cripe",
year = "2004",
month = "1",
doi = "10.1016/S0145-2126(03)00181-4",
language = "English",
volume = "28",
pages = "49--52",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Phase II study of low-dose topotecan in myelodysplastic syndromes

T2 - A Hoosier Oncology Group (HOG) study

AU - Vaena, Daniel A.

AU - Walker, Paul

AU - Pennington, Kenneth

AU - Stephens, Anthony

AU - Stender, Michael J.

AU - Yiannoutsos, Constantin

AU - Young, Carol

AU - Stoner, Cindy

AU - Cripe, Larry

PY - 2004/1

Y1 - 2004/1

N2 - Topotecan has demonstrable activity in high-risk MDS and CMMoL. However, the significant toxicity of topotecan administered at a dose of 2mg/m 2 i.v. daily for 5 days as a continuous infusion limits its use in older patients. Therefore, we studied topotecan 1.5mg/m2 per day i.v. over 2h for three consecutive days in 20 patients with high-risk MDS (12 RAEB; 4 RAEB-T; 4 CMMoL). Cycles were given every 4-6 weeks. Fifteen patients were evaluable for response. Only one patient achieved a durable complete remission (CR). There were three deaths within the first cycle of therapy. Severe myelosupression was the most common toxicity. Grades 3-4 infections were documented in four patients. We conclude that topotecan administered at this dose and schedule has no clinically significant activity.

AB - Topotecan has demonstrable activity in high-risk MDS and CMMoL. However, the significant toxicity of topotecan administered at a dose of 2mg/m 2 i.v. daily for 5 days as a continuous infusion limits its use in older patients. Therefore, we studied topotecan 1.5mg/m2 per day i.v. over 2h for three consecutive days in 20 patients with high-risk MDS (12 RAEB; 4 RAEB-T; 4 CMMoL). Cycles were given every 4-6 weeks. Fifteen patients were evaluable for response. Only one patient achieved a durable complete remission (CR). There were three deaths within the first cycle of therapy. Severe myelosupression was the most common toxicity. Grades 3-4 infections were documented in four patients. We conclude that topotecan administered at this dose and schedule has no clinically significant activity.

KW - Acute myeloid leukemia

KW - Induction

KW - Low-dose chemotherapy

KW - Mortality

KW - Myelodysplastic syndromes

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0242551835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242551835&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(03)00181-4

DO - 10.1016/S0145-2126(03)00181-4

M3 - Article

C2 - 14630080

AN - SCOPUS:0242551835

VL - 28

SP - 49

EP - 52

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 1

ER -